The global custom antibody market is a rapidly expanding sector of the pharmaceutical and biotechnology industries. According to Transparency Market Research (TMR), the market, valued at $442.3 million in 2023, is projected to reach a staggering $1 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5% between 2023 and 2033.
Custom antibodies, designed to target specific antigens, play a crucial role in the fight against numerous diseases, including cancer and various infectious diseases. The National Institute of Health (NIH), among other organizations, has recognized the importance of custom antibodies, providing over $540 million in 2021 for monoclonal antibody research and development.
Impact on Pharmaceutical and Biotechnology Industries
The custom antibody market’s expansion has significant implications for the pharmaceutical and biotechnology industries. As the primary end-users, these industries are registering a CAGR of 7.9%, driven by increased investments in emerging countries and rising research and development initiatives for innovative treatments.
For instance, the Australian government allocated $3.6 billion to support science innovation for basic research from 2020 to 2021, focusing on developing new treatments for lung conditions. Similarly, Japan invested $970 million in regenerative medicine in April 2022, further bolstering the market growth.
Key Players in the Market
Key players in the global custom antibody market include Thermo Fisher Scientific and Abcam Plc. Thermo Fisher Scientific recently launched a custom antibody development designed to streamline the development process. Meanwhile, Abcam acquired Bio Vision, a company specializing in assay kits and custom antibodies development and manufacturing.
The custom antibody market is segmented by service, type, source, research area, and end-user. The ‘service’ category is dominated by antibody development, which is expected to grow at a CAGR of 8.2% from 2023-2033. The ‘type’ category includes monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other custom antibodies. The ‘source’ category is segmented into mice, rabbits, and other sources.
Research areas encompass oncology, infectious disease, neurobiology, stem cells, immunology, cardiovascular disease, and other research areas. End-users include pharmaceutical & biotechnological industries, academic & research institutions, and contract research organizations.
Potential Impact on Chester County, Pennsylvania’s Life Sciences Industry
The growth of the global custom antibody market could also have potential implications for local economies, such as Chester County’s life sciences industry. As investment in antibody research increases, there might be an opportunity for the county’s life sciences sector to attract funding, partnerships, and collaborations with leading companies in the custom antibody market.
Moreover, the rising demand for custom antibodies could lead to increased job opportunities in research and development, production, and other related roles. This could contribute to economic growth and the strengthening of the county’s position as a hub for life sciences.
In conclusion, the global custom antibody market is set for significant growth, driven by increased investments in research and development, advancements in technology, and the rising need for effective treatments for various diseases. This growth presents exciting opportunities for pharmaceutical and biotechnology companies, research institutions, and regions like Chester County, where the life sciences industry plays a significant role.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.